Int J Ophthalmol:季节过敏性结膜炎风险因子调查

2018-09-22 AlexYang MedSci原创

最近,有研究人员通过皮肤过敏测试和调查问卷中获得的数据,分析了发展为季节过敏性结膜炎(SAC)可能的风险因素。研究包括了75名SAC患者和71未诊断为SAC的对照。调查的时间为2016年3月到2016年12月之间。研究人员对所有的参与者进行了皮刺试验,并测量了血清总lgE和25-OH维他命D的水平。研究人员同时也调查了SAC发生的可能风险因素,比如抽烟、对乙酰氨基酚接触、维生素D补充和环境因素等。

最近,有研究人员通过皮肤过敏测试和调查问卷中获得的数据,分析了发展为季节过敏性结膜炎(SAC)可能的风险因素。研究包括了75名SAC患者和71未诊断为SAC的对照。调查的时间为2016年3月到2016年12月之间。研究人员对所有的参与者进行了皮刺试验,并测量了血清总lgE和25-OH维他命D的水平。研究人员同时也调查了SAC发生的可能风险因素,比如抽烟、对乙酰氨基酚接触、维生素D补充和环境因素等。

研究发现,患有SAC的患者具有产前孕产妇扑热息痛接触历史。同样的,在同样的患者组中,产后维生素D补充的持续时间也是更短的(P<0.001)。然而,在SAC和母亲抗生素接触、母亲抽烟、生产方式和出生体重以及宠物的存在均没有发现明显的相关性。更多的是,患有SAC的患者更可能患有哮喘、过敏性鼻炎和口服过敏性综合征。研究人员同样发现SAC患者的母亲和兄弟姐妹更可能患有过敏性结膜炎。同样的,他们的父亲更可能患有过敏性鼻炎。

最后,研究人员指出,产前母亲扑热息痛接触和产后更短时间的维生素D补充在SAC发展过程中具有重要作用。因此,预防不必要的妊娠期扑热息痛摄入和妊娠期维生素D的补充能够有效的减少SAC的的起始和发展。

原始出处:

Dogan Ü, Agca S. Investigation of possible risk factors in the development of seasonal allergic conjunctivitis. Int J Ophthalmol. Sep 18 2018

本文系梅斯医学(MedSci)原创编译和整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1677497, encodeId=d53216e7497c2, content=<a href='/topic/show?id=2ebbe881920' target=_blank style='color:#2F92EE;'>#结膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78819, encryptionId=2ebbe881920, topicName=结膜炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=803827523485, createdName=tm10051990, createdTime=Fri Mar 15 21:01:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645527, encodeId=f83c164552e8a, content=<a href='/topic/show?id=f09c9405003' target=_blank style='color:#2F92EE;'>#过敏性结膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94050, encryptionId=f09c9405003, topicName=过敏性结膜炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bee23217751, createdName=mhzhuang@stu.e, createdTime=Tue Feb 05 16:01:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047022, encodeId=0e96204e022bb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Aug 15 08:01:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468693, encodeId=4a6f1468693a3, content=<a href='/topic/show?id=a19b4540688' target=_blank style='color:#2F92EE;'>#季节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45406, encryptionId=a19b4540688, topicName=季节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf986929326, createdName=30397606, createdTime=Mon Sep 24 02:01:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529270, encodeId=c84f15292e0b3, content=<a href='/topic/show?id=6eb91008e03b' target=_blank style='color:#2F92EE;'>#风险因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100870, encryptionId=6eb91008e03b, topicName=风险因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2d411920658, createdName=cenghis, createdTime=Mon Sep 24 02:01:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541391, encodeId=2f3c15413911b, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Mon Sep 24 02:01:00 CST 2018, time=2018-09-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1677497, encodeId=d53216e7497c2, content=<a href='/topic/show?id=2ebbe881920' target=_blank style='color:#2F92EE;'>#结膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78819, encryptionId=2ebbe881920, topicName=结膜炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=803827523485, createdName=tm10051990, createdTime=Fri Mar 15 21:01:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645527, encodeId=f83c164552e8a, content=<a href='/topic/show?id=f09c9405003' target=_blank style='color:#2F92EE;'>#过敏性结膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94050, encryptionId=f09c9405003, topicName=过敏性结膜炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bee23217751, createdName=mhzhuang@stu.e, createdTime=Tue Feb 05 16:01:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047022, encodeId=0e96204e022bb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Aug 15 08:01:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468693, encodeId=4a6f1468693a3, content=<a href='/topic/show?id=a19b4540688' target=_blank style='color:#2F92EE;'>#季节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45406, encryptionId=a19b4540688, topicName=季节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf986929326, createdName=30397606, createdTime=Mon Sep 24 02:01:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529270, encodeId=c84f15292e0b3, content=<a href='/topic/show?id=6eb91008e03b' target=_blank style='color:#2F92EE;'>#风险因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100870, encryptionId=6eb91008e03b, topicName=风险因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2d411920658, createdName=cenghis, createdTime=Mon Sep 24 02:01:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541391, encodeId=2f3c15413911b, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Mon Sep 24 02:01:00 CST 2018, time=2018-09-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1677497, encodeId=d53216e7497c2, content=<a href='/topic/show?id=2ebbe881920' target=_blank style='color:#2F92EE;'>#结膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78819, encryptionId=2ebbe881920, topicName=结膜炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=803827523485, createdName=tm10051990, createdTime=Fri Mar 15 21:01:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645527, encodeId=f83c164552e8a, content=<a href='/topic/show?id=f09c9405003' target=_blank style='color:#2F92EE;'>#过敏性结膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94050, encryptionId=f09c9405003, topicName=过敏性结膜炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bee23217751, createdName=mhzhuang@stu.e, createdTime=Tue Feb 05 16:01:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047022, encodeId=0e96204e022bb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Aug 15 08:01:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468693, encodeId=4a6f1468693a3, content=<a href='/topic/show?id=a19b4540688' target=_blank style='color:#2F92EE;'>#季节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45406, encryptionId=a19b4540688, topicName=季节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf986929326, createdName=30397606, createdTime=Mon Sep 24 02:01:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529270, encodeId=c84f15292e0b3, content=<a href='/topic/show?id=6eb91008e03b' target=_blank style='color:#2F92EE;'>#风险因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100870, encryptionId=6eb91008e03b, topicName=风险因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2d411920658, createdName=cenghis, createdTime=Mon Sep 24 02:01:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541391, encodeId=2f3c15413911b, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Mon Sep 24 02:01:00 CST 2018, time=2018-09-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1677497, encodeId=d53216e7497c2, content=<a href='/topic/show?id=2ebbe881920' target=_blank style='color:#2F92EE;'>#结膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78819, encryptionId=2ebbe881920, topicName=结膜炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=803827523485, createdName=tm10051990, createdTime=Fri Mar 15 21:01:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645527, encodeId=f83c164552e8a, content=<a href='/topic/show?id=f09c9405003' target=_blank style='color:#2F92EE;'>#过敏性结膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94050, encryptionId=f09c9405003, topicName=过敏性结膜炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bee23217751, createdName=mhzhuang@stu.e, createdTime=Tue Feb 05 16:01:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047022, encodeId=0e96204e022bb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Aug 15 08:01:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468693, encodeId=4a6f1468693a3, content=<a href='/topic/show?id=a19b4540688' target=_blank style='color:#2F92EE;'>#季节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45406, encryptionId=a19b4540688, topicName=季节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf986929326, createdName=30397606, createdTime=Mon Sep 24 02:01:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529270, encodeId=c84f15292e0b3, content=<a href='/topic/show?id=6eb91008e03b' target=_blank style='color:#2F92EE;'>#风险因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100870, encryptionId=6eb91008e03b, topicName=风险因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2d411920658, createdName=cenghis, createdTime=Mon Sep 24 02:01:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541391, encodeId=2f3c15413911b, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Mon Sep 24 02:01:00 CST 2018, time=2018-09-24, status=1, ipAttribution=)]
    2018-09-24 30397606
  5. [GetPortalCommentsPageByObjectIdResponse(id=1677497, encodeId=d53216e7497c2, content=<a href='/topic/show?id=2ebbe881920' target=_blank style='color:#2F92EE;'>#结膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78819, encryptionId=2ebbe881920, topicName=结膜炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=803827523485, createdName=tm10051990, createdTime=Fri Mar 15 21:01:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645527, encodeId=f83c164552e8a, content=<a href='/topic/show?id=f09c9405003' target=_blank style='color:#2F92EE;'>#过敏性结膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94050, encryptionId=f09c9405003, topicName=过敏性结膜炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bee23217751, createdName=mhzhuang@stu.e, createdTime=Tue Feb 05 16:01:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047022, encodeId=0e96204e022bb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Aug 15 08:01:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468693, encodeId=4a6f1468693a3, content=<a href='/topic/show?id=a19b4540688' target=_blank style='color:#2F92EE;'>#季节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45406, encryptionId=a19b4540688, topicName=季节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf986929326, createdName=30397606, createdTime=Mon Sep 24 02:01:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529270, encodeId=c84f15292e0b3, content=<a href='/topic/show?id=6eb91008e03b' target=_blank style='color:#2F92EE;'>#风险因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100870, encryptionId=6eb91008e03b, topicName=风险因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2d411920658, createdName=cenghis, createdTime=Mon Sep 24 02:01:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541391, encodeId=2f3c15413911b, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Mon Sep 24 02:01:00 CST 2018, time=2018-09-24, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1677497, encodeId=d53216e7497c2, content=<a href='/topic/show?id=2ebbe881920' target=_blank style='color:#2F92EE;'>#结膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78819, encryptionId=2ebbe881920, topicName=结膜炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=803827523485, createdName=tm10051990, createdTime=Fri Mar 15 21:01:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645527, encodeId=f83c164552e8a, content=<a href='/topic/show?id=f09c9405003' target=_blank style='color:#2F92EE;'>#过敏性结膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94050, encryptionId=f09c9405003, topicName=过敏性结膜炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bee23217751, createdName=mhzhuang@stu.e, createdTime=Tue Feb 05 16:01:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047022, encodeId=0e96204e022bb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Aug 15 08:01:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468693, encodeId=4a6f1468693a3, content=<a href='/topic/show?id=a19b4540688' target=_blank style='color:#2F92EE;'>#季节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45406, encryptionId=a19b4540688, topicName=季节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf986929326, createdName=30397606, createdTime=Mon Sep 24 02:01:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529270, encodeId=c84f15292e0b3, content=<a href='/topic/show?id=6eb91008e03b' target=_blank style='color:#2F92EE;'>#风险因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100870, encryptionId=6eb91008e03b, topicName=风险因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2d411920658, createdName=cenghis, createdTime=Mon Sep 24 02:01:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541391, encodeId=2f3c15413911b, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Mon Sep 24 02:01:00 CST 2018, time=2018-09-24, status=1, ipAttribution=)]

相关资讯

FDA批准用于过敏性结膜炎的局部滴眼液

西替利嗪是与组胺受体位点竞争性结合以减少肿胀、瘙痒和血管舒张的第二代抗组胺药(H1受体拮抗剂)。日前,美国食品和药物管理局(FDA)已经批准了抗组胺药西替利嗪作为首个局部眼部制剂用于治疗与过敏性结膜炎相关的眼部瘙痒。据悉,西替利嗪眼用溶液0.24%(Zerviate,Nicox SA)的疗效已在具有过敏性结膜炎病史患者的三项随机、双盲、安慰剂对照、结膜抗原攻击临床试验中证实。

Int Ophthalmol.:过敏性结膜炎中亚硝酸盐、新蝶呤和的色氨酸降解水平变化!

土耳其埃尔祖鲁姆眼科的Cinici E近日在Int Ophthalmol杂志上发表了一项有趣的工作,标题为"Nitrite, neopterin levels and tryptophan degradation in allergic conjunctivitis",Th1型免疫反应和一氧化氮代谢可能参与过敏性炎症,因此他们主要研究了在Th1型免疫反应和一氧化氮代谢过程中新蝶呤水平和色氨酸降解的

我国过敏性结膜炎诊断和治疗专家共识(2018年)

在我国,过敏性结膜炎的诊断标准和治疗方案在相当长一段时间内都缺乏统一认识,多数眼科医师仅依靠个人临床经验进行诊断和治疗,临床效果难以保障。近年来我国眼科诊断和治疗技术快速发展,有关过敏性结膜炎的基础和临床研究不断深入,适时规范我国眼科医师对过敏性结膜炎的诊断和治疗工作十分必要。为此,中华医学会眼科学分会角膜病学组组织我国角膜病领域专家,紧紧围绕过敏性结膜炎基础和临床研究的热点,以国内外循证医学研究